A BILL 
To amend title XVIII of the Social Security Act to require 
pharmacy-negotiated price concessions to be included in 
negotiated prices at the point-of-sale under part D of 
the Medicare program, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Phair Pricing Act of 
4
2019’’. 
5
22:16 Feb 19, 2019
H1034
2 
•HR 1034 IH
SEC. 2. REQUIRING PHARMACY-NEGOTIATED PRICE CON-
1
CESSIONS AND PHARMACY INCENTIVE PAY-
2
MENTS AND ADJUSTMENTS TO BE INCLUDED 
3
IN NEGOTIATED PRICES AT THE POINT-OF- 
4
SALE UNDER PART D OF THE MEDICARE PRO-
5
GRAM. 
6
Section 1860D–2(d)(1)(B) of the Social Security Act 
7
(42 U.S.C. 1395w–102(d)(1)(B)) is amended— 
8
(1) by striking ‘‘PRICES.—For purposes’’ and 
9
inserting ‘‘PRICES.— 
10
‘‘(i) IN
GENERAL.—For purposes’’; 
11
and 
12
(2) by adding at the end the following new 
13
clauses: 
14
‘‘(ii) 
PRICES
NEGOTIATED
WITH 
15
PHARMACY AT POINT-OF-SALE.— 
16
‘‘(I) IN
GENERAL.—Subject to 
17
subclause (III), for plan years begin-
18
ning on or after January 1, 2020, ne-
19
gotiated prices for covered part D 
20
drugs described in clause (i) provided 
21
under a prescription drug plan, in-
22
cluding all contingent and noncontin-
23
gent concessions, adjustments, pay-
24
ments, and fees (including dispensing 
25
fees) negotiated with the pharmacy 
26
22:16 Feb 19, 2019
H1034
3 
•HR 1034 IH
dispensing such drug, shall be pro-
1
vided at the point-of-sale of such 
2
drug. Such negotiated price shall not 
3
include any incentive payments and 
4
adjustments or any other contingent 
5
concessions, adjustments, payments, 
6
or fees that increase the amount of 
7
such negotiated price. 
8
‘‘(II) APPLICATION
OF
PHAR-
9
MACY INCENTIVE PAYMENTS AND AD-
10
JUSTMENTS.— 
11
‘‘(aa) 
IN
GENERAL.—For 
12
plan years beginning on or after 
13
January 1, 2020, a PDP spon-
14
sor— 
15
‘‘(AA) shall apply a 
16
system under which incen-
17
tive payments and adjust-
18
ments using only quality 
19
measures established by the 
20
Secretary under item (bb) 
21
are made to a pharmacy 
22
with respect to payment for 
23
covered part D drugs dis-
24
22:16 Feb 19, 2019
H1034
4 
•HR 1034 IH
pensed by such pharmacy; 
1
and 
2
‘‘(BB) may not apply 
3
any other incentive pay-
4
ments and adjustments with 
5
respect to such payment 
6
outside of such system. 
7
Application of such system may 
8
not result in a decrease in reim-
9
bursement to such pharmacy for 
10
such drug after the point-of-sale 
11
of such drug. 
12
‘‘(bb) STANDARD PHARMACY 
13
QUALITY
MEASURES.—The Sec-
14
retary shall establish standard 
15
quality measures that may be 
16
used in a system described in 
17
item (aa). Such measures shall 
18
be— 
19
‘‘(AA) focused on im-
20
proving patient health out-
21
comes; 
22
‘‘(BB) 
standardized 
23
across PDP sponsors; 
24
22:16 Feb 19, 2019
H1034
5 
•HR 1034 IH
‘‘(CC) 
pharmacy-spe-
1
cific in application; 
2
‘‘(DD) relevant to the 
3
type of pharmacy concerned 
4
(such 
as 
specialty 
phar-
5
macies), taking into account 
6
the items and services fur-
7
nished by the pharmacy and 
8
the 
patient 
population 
9
served by the pharmacy; 
10
‘‘(EE) 
applied 
only 
11
when relevant to the specific 
12
drug (or drug class of such 
13
drug) being furnished by the 
14
pharmacy or when relevant 
15
to management of the condi-
16
tion for which such drug has 
17
been prescribed; and 
18
‘‘(FF) based on achiev-
19
able and proven criteria 
20
measuring pharmacy per-
21
formance over which the 
22
pharmacy has meaningful 
23
control and ability to influ-
24
ence. 
25
22:16 Feb 19, 2019
H1034
6 
•HR 1034 IH
In establishing such standards, 
1
the Secretary shall consult with 
2
stakeholders, 
including 
PDP 
3
sponsors and MA organizations, 
4
pharmacies 
across 
pharmacy 
5
practice types, pharmacy benefit 
6
managers, patient advocacy orga-
7
nizations, drug manufacturers, 
8
appropriate standard-setting or-
9
ganizations, and other entities 
10
determined appropriate by the 
11
Secretary. 
12
‘‘(III) NO
INCREASE
IN
COST 
13
SHARING.—Subclause (I) shall not 
14
apply in the case where application of 
15
such subclause would increase the 
16
amount owed by an individual in cost 
17
sharing above the amount such indi-
18
vidual would have owed in cost shar-
19
ing without application of such sub-
20
clause. 
21
‘‘(IV) DISCREPANCIES BETWEEN 
22
NEGOTIATED PRICES AND ACTUAL RE-
23
IMBURSEMENT.—In the case that the 
24
Secretary determines that the nego-
25
22:16 Feb 19, 2019
H1034
7 
•HR 1034 IH
tiated price of a PDP sponsor applied 
1
at the point-of-sale with respect to a 
2
covered part D drug for a year dis-
3
pensed by a pharmacy was greater 
4
than the total reimbursement made to 
5
such pharmacy for such drug for such 
6
year, such sponsor shall, not later 
7
than 90 days after receiving notice of 
8
such determination, furnish to the 
9
pharmacy that dispensed such drug 
10
and to the Secretary a written expla-
11
nation of why such negotiated price 
12
was greater than such reimbursement. 
13
‘‘(V) SPECIALTY
PHARMACY.— 
14
For purposes of carrying out this 
15
clause 
(including 
subclause 
16
(II)(bb)(DD)), the Secretary shall, not 
17
later than December 31, 2019, define 
18
the term ‘specialty pharmacy’ in con-
19
sultation with relevant stakeholders. 
20
‘‘(VI) 
DEFINITIONS.—In 
this 
21
clause: 
22
‘‘(aa) INCENTIVE PAYMENTS 
23
AND
ADJUSTMENTS.—The term 
24
‘incentive payments and adjust-
25
22:16 Feb 19, 2019
H1034
8 
•HR 1034 IH
ments’ means, with respect to 
1
payment to a pharmacy by a 
2
PDP sponsor for a covered part 
3
D drug, any prospective or retro-
4
spective price concessions, re-
5
bates, discounts, fees, reconcili-
6
ation adjustments, bonuses, per-
7
formance payments, incentives, 
8
and any other adjustment to 
9
such 
payment 
determined 
10
through the use of a quality 
11
measure, regardless of when such 
12
payments and adjustments are 
13
applied. Such term does not in-
14
clude any manufacturer rebates 
15
or concessions made with respect 
16
to such drug. 
17
‘‘(bb) QUALITY MEASURE.— 
18
The 
term 
‘quality 
measure’ 
19
means performance criteria used 
20
by a PDP sponsor (including an 
21
entity that contracts with such 
22
sponsor, such as a pharmacy ben-
23
efit manager) to determine the 
24
22:16 Feb 19, 2019
H1034
9 
•HR 1034 IH
amount or applicability of incen-
1
tive payments and adjustments. 
2
‘‘(cc) PDP SPONSOR.—The 
3
term ‘PDP sponsor’ includes an 
4
MA organization offering an MA- 
5
PD plan under part C and an en-
6
tity that contracts with such 
7
sponsor or organization, such as 
8
a pharmacy benefit manager. 
9
‘‘(iii) REASONABLE
REIMBURSEMENT 
10
REQUIREMENT.—In no case may a nego-
11
tiated price (as described in clause (ii)(I)) 
12
for a covered part D drug furnished by a 
13
pharmacy during a plan year beginning on 
14
or after January 1, 2020, be less than 
15
such pharmacy’s cost of purchasing and 
16
dispensing such drug and providing such 
17
other services associated with furnishing 
18
such drug as may be specified by the Sec-
19
retary. 
20
‘‘(iv) CLAIM
REIMBURSEMENT
DIS-
21
CLOSURE
REQUIREMENTS.—With respect 
22
to payment made by a PDP sponsor to a 
23
pharmacy for a covered part D drug fur-
24
nished by such pharmacy during a plan 
25
22:16 Feb 19, 2019
H1034
10 
•HR 1034 IH
year beginning on or after January 1, 
1
2020, such sponsor shall promptly furnish 
2
all pricing components including the Net-
3
work Reimbursement ID used to price the 
4
claim, any fees, pharmacy price conces-
5
sions, discounts, incentives or any other 
6
forms of remuneration that affect payment 
7
and pricing of the claim as part of the 
8
claim adjudication response at the point-of- 
9
sale. All aforementioned items, including 
10
Network Reimbursement ID, fees, phar-
11
macy price concessions, discounts, incen-
12
tives, or any other forms of remuneration 
13
that affect payment and pricing of the 
14
claim shall each be identified in a predeter-
15
mined line item in the remittance advice 
16
that is standard across the industry. The 
17
Part D sponsor shall include suitable 
18
claim-level detail on the electronic remit-
19
tance advice that accompanies each pay-
20
ment. This claim-level detail shall include, 
21
in an industry standardized format, all 
22
fields needed to properly identify the claim, 
23
including the Claim Authorization Number, 
24
date of service, date of payment remit-
25
22:16 Feb 19, 2019
H1034
11 
•HR 1034 IH
tance, ingredient cost reimbursed, dis-
1
pensing fee reimbursed, payment amounts 
2
including the Network ID used to price the 
3
claim, the specific dollar amounts and the 
4
appropriate qualifier codes for each pay-
5
ment adjustment including fees, pharmacy 
6
price concessions, or incentives. 
7
‘‘(v) VIOLATION
PROCESS.—A PDP 
8
sponsor shall participate in any process es-
9
tablished by the Secretary for purposes of 
10
determining whether such sponsor has vio-
11
lated a provision of clauses (ii) through 
12
(iv).’’. 
13
SEC. 3. PHARMACY BENEFIT MANAGER PROVISION OF IN-
14
FORMATION. 
15
(a) IN GENERAL.—Section 1150A(b)(2) of the Social 
16
Security Act (42 U.S.C. 1320b–23(b)(2)) is amended by 
17
striking ‘‘excluding’’ and inserting ‘‘including’’. 
18
(b) EFFECTIVE DATE.—The amendment made by 
19
subsection (a) shall apply with respect to contract years 
20
beginning on or after January 1, 2020. 
21
Æ 
22:16 Feb 19, 2019
H1034
